Health Care · Pharmaceutical Preparations

PBLS Parabilis Medicines Inc SEC Filings & Insider Trading Activity 2026

company
CIK 165767726 filings

PBLS at a glance

Parabilis Medicines Inc (PBLS, SEC CIK 1657677) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Parabilis Medicines Inc (PBLS) shares worth $627.8 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on July 22, 2026 of 47,250 shares at $29.77 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
24 funds
$627.8M · +8 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added regulatory risk: June 2026 FDA draft guidance may require additional evidence despite single-trial pathway
  • Most material clinical update: March 2026 injectable formulation paused after Grade 1 and Grade 2 injection-site reactions
  • AI compliance risk: EU Artificial Intelligence Act obligations became effective August 2, 2026
  • Operational risk: Alcami remains the sole drug-product supplier
  • Financial risk: $1,072.9 million cash, cash equivalents and marketable securities funding operations into 2030

Management Discussion & Analysis

  • Quarterly revenue $2.1M vs $0, including $0.7M Regeneron and $1.4M Altos collaboration revenue
  • Net loss $44.5M vs $33.5M, operating expenses $56.9M vs $34.8M
  • R&D highest spender: zolucatetide $17.8M, up 118.9% YoY; ERG degrader $1.2M, down 16.1%
  • Cash, equivalents and marketable securities $1,072.9M, funding operations into 2030
  • IPO and private placement generated $787.9M net; Regeneron upfront payment $50.0M
  • Near-term outlook: Phase 3 zolucatetide trial planned for first half 2027; substantial additional funding required

AI summary of the PBLS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal quarter ended September 30, 2026 results announced
  • Press release includes Parabilis Medicines’ financial results and business highlights

Item EX-99.1: Item EX-99.1

  • Zolucatetide desmoid-tumor data: 72.2% ORR at 32 weeks, 100% DCR across 46 patients, with no treatment-related discontinuations
  • FDA-aligned PEDESTAL Phase 3 design, planned launch in first half 2027 and topline results anticipated in 2029
Filed Nov 5, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Headquarters footprint expands by 33,525 square feet at 20 Acorn Park Drive beginning January 1, 2028
  • Rent on added space starts January 1, 2029, deferring cash outflows for one year
Filed Sep 15, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated Phase 1/2 zolucatetide data planned for oral presentation at ESMO Congress 2026
  • Data concern patients with desmoid tumors, a key clinical development milestone

AI summaries of PBLS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PBLS

Don't miss the next PBLS filing

  • Alerts as it files. A push when PBLS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PBLS, by share count.
  • Ask anything. An AI agent that reads every PBLS filing and answers with sources.

PBLS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Tendler CraigAAug 22, 2026-
RA CAPITAL MANAGEMENT, L.P.BuyJul 22, 2026$29.77
RA CAPITAL MANAGEMENT, L.P.BuyJul 21, 2026$30.00
RA CAPITAL MANAGEMENT, L.P.BuyJul 21, 2026$27.96
RA CAPITAL MANAGEMENT, L.P.BuyJul 21, 2026$29.17
RA CAPITAL MANAGEMENT, L.P.BuyJul 20, 2026$27.72
RA CAPITAL MANAGEMENT, L.P.BuyJul 20, 2026$27.13
SEBULSKY ALANBuyJun 15, 2026$26.00

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PBLS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PBLS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202624$627.8M
Q2 202616$664.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 40 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PBLS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
8-KNov 5, 2026Analysis-
8-KSep 15, 2026Analysis-
8-KSep 2, 2026Analysis-
4Aug 25, 2026--
8-KAug 25, 2026Analysis-
10-QAug 13, 2026-
8-KAug 13, 2026Analysis-
4Jul 22, 2026--
4Jun 29, 2026--
4Jun 16, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 15, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--

Related Health Care companies

All Health Care →

PBLS SEC filings: frequently asked questions

Which institutions hold PBLS stock?

As of September 30, 2026, the largest Parabilis Medicines Inc (PBLS) holders among the 13F filers tracked by SignalX were Alphabet Inc ($158.9 million), Regeneron Pharmaceuticals ($134.5 million), BlackRock ($90.1 million), Vanguard Portfolio Management LLC ($51.1 million), Vanguard Capital Management LLC ($50.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did PBLS report in its latest 8-K?

Parabilis Medicines Inc (PBLS) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal quarter ended September 30, 2026 results announced.

What are the latest PBLS SEC filings?

Parabilis Medicines Inc (PBLS) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 25, 2026.

What is PBLS's SEC CIK number?

Parabilis Medicines Inc (PBLS)'s SEC Central Index Key (CIK) is 1657677. EDGAR lists every PBLS filing under that number.

Ask anything about PBLS

The research agent reads PBLS's filings, financials, insider trades and 13F holders, then answers with sources.